Patents by Inventor Satoshi Inouye

Satoshi Inouye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11268106
    Abstract: The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a GC content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a GC content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: March 8, 2022
    Assignee: JNC CORPORATION
    Inventor: Satoshi Inouye
  • Patent number: 10988741
    Abstract: A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: April 27, 2021
    Assignee: JNC CORPORATION
    Inventors: Satoshi Inouye, Yuiko Miura, Junichi Sato
  • Patent number: 10907134
    Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.
    Type: Grant
    Filed: October 30, 2019
    Date of Patent: February 2, 2021
    Assignee: JNC CORPORATION
    Inventors: Satoshi Inouye, Junichi Sato
  • Publication number: 20200056162
    Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.
    Type: Application
    Filed: October 30, 2019
    Publication date: February 20, 2020
    Applicant: JNC CORPORATION
    Inventors: Satoshi INOUYE, Junichi SATO
  • Patent number: 10519428
    Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: December 31, 2019
    Assignee: JNC CORPORATION
    Inventors: Satoshi Inouye, Junichi Sato
  • Patent number: 10393732
    Abstract: The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: August 27, 2019
    Assignee: JNC Corporation
    Inventor: Satoshi Inouye
  • Publication number: 20190256826
    Abstract: A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.
    Type: Application
    Filed: May 6, 2019
    Publication date: August 22, 2019
    Applicant: JNC CORPORATION
    Inventors: Satoshi INOUYE, Yuiko MIURA, Junichi SATO
  • Patent number: 10377995
    Abstract: A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: August 13, 2019
    Assignee: JNC CORPORATION
    Inventors: Satoshi Inouye, Yuiko Miura, Junichi Sato
  • Publication number: 20190100770
    Abstract: The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a GC content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a GC content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes.
    Type: Application
    Filed: December 11, 2018
    Publication date: April 4, 2019
    Applicant: JNC CORPORATION
    Inventor: Satoshi Inouye
  • Patent number: 10196650
    Abstract: The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a GC content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a GC content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: February 5, 2019
    Assignee: JNC CORPORATION
    Inventor: Satoshi Inouye
  • Patent number: 10184116
    Abstract: A novel luciferase that distinct from conventional luciferase has been desired. A luciferase mutant comprising the amino acid sequence of SEQ ID NO: 2 substituted at tyrosine at the position of 138, and at least 3 positions selected from the group consisting of isoleucine at the position of 90, proline at the position of 115, glutamine at the position of 124, and asparagine at the position of 166.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: January 22, 2019
    Assignee: JNC CORPORATION
    Inventors: Satoshi Inouye, Junichi Sato
  • Patent number: 10156557
    Abstract: The invention provides calcium-binding photoproteins which can detect light emission with a higher sensitivity. The proteins of the invention comprising the amino acid sequence of SEQ ID NO: 2 can be used for the detection and measurement of calcium ions. The proteins of the invention are useful as reporter proteins, luminescent markers, etc. The polynucleotides of the invention are useful as reporter genes, etc.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: December 18, 2018
    Assignee: JNC CORPORATION
    Inventors: Satoshi Inouye, Yuiko Sahara
  • Publication number: 20180216085
    Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.
    Type: Application
    Filed: March 26, 2018
    Publication date: August 2, 2018
    Applicant: JNC CORPORATION
    Inventors: Satoshi INOUYE, Junichi SATO
  • Patent number: 10006009
    Abstract: There has been a demand for a codon-optimized gene for the mutated catalytic domain of Oplophorus luciferase, which is capable of efficiently expressing a protein both in a cultured animal cell and Escherichia coli. There has also been a demand for a substrate coelenterazine analog showing a higher activity than that of native 19 kDa protein. The invention provides a polynucleotide comprising a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 2. According to the invention, bis-coelenterazine is used as a substrate coelenterazine analog suitable for the photoprotein encoded by the polynucleotide comprising the polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 2.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: June 26, 2018
    Assignee: JNC CORPORATION
    Inventors: Satoshi Inouye, Junichi Sato
  • Publication number: 20180171356
    Abstract: The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a GC content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a GC content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes.
    Type: Application
    Filed: February 26, 2018
    Publication date: June 21, 2018
    Applicant: JNC CORPORATION
    Inventor: Satoshi Inouye
  • Publication number: 20180119112
    Abstract: A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.
    Type: Application
    Filed: December 7, 2017
    Publication date: May 3, 2018
    Applicant: JNC CORPORATION
    Inventors: Satoshi INOUYE, Yuiko MIURA, Junichi SATO
  • Patent number: 9957487
    Abstract: Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: May 1, 2018
    Assignee: JNC CORPORATION
    Inventors: Satoshi Inouye, Junichi Sato
  • Patent number: 9938539
    Abstract: The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a GC content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a GC content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: April 10, 2018
    Assignee: JNC CORPORATION
    Inventor: Satoshi Inouye
  • Patent number: 9868941
    Abstract: A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: January 16, 2018
    Assignee: JNC CORPORATION
    Inventors: Satoshi Inouye, Yuiko Miura, Junichi Sato
  • Publication number: 20180011082
    Abstract: The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs.
    Type: Application
    Filed: September 15, 2017
    Publication date: January 11, 2018
    Applicant: JNC CORPORATION
    Inventor: Satoshi INOUYE